70 search results for Hypoxia
| # | SuperPathway Name | Genes Count | Relevance Score | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 978 | 2.361 | |||||
|
||||||||
| 2 | Hypoxia-mediated EMT and stemness | 2 | 1.500 | |||||
|
||||||||
| 3 | Cellular responses to stimuli | 802 | 1.173 | |||||
|
||||||||
| 4 | Type 2 papillary renal cell carcinoma | 34 | 0.829 | |||||
|
||||||||
| 5 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | 17 | 0.829 | |||||
|
||||||||
| 6 | HIF1Alpha Pathway | 54 | 0.829 | |||||
|
||||||||
| 7 | HIF Enhancers | 24 | 0.718 | |||||
|
||||||||
| 8 | Angiogenesis (CST) | 89 | 0.718 | |||||
|
||||||||
| 9 | Translational Control | 190 | 0.718 | |||||
|
||||||||
| 10 | Photodynamic therapy-induced HIF-1 survival signaling | 37 | 0.718 | |||||
|
||||||||
| 11 | HIF-1-alpha transcription factor network | 65 | 0.718 | |||||
|
||||||||
| 12 | Markers of kidney cell lineage | 59 | 0.718 | |||||
|
||||||||
| 13 | HIF-2-alpha transcription factor network | 30 | 0.586 | |||||
|
||||||||
| 14 | PI3K-Akt signaling pathway | 390 | 0.586 | |||||
|
||||||||
| 15 | Vitamin D receptor pathway | 185 | 0.586 | |||||
|
||||||||
| 16 | MicroRNA for targeting cancer growth and vascularization in glioblastoma | 7 | 0.586 | |||||
|
||||||||
| 17 | Metabolism of proteins | 1970 | 0.586 | |||||
|
||||||||
| 18 | Class I MHC mediated antigen processing and presentation | 855 | 0.586 | |||||
|
||||||||
| 19 | GDNF signaling | 132 | 0.415 | |||||
|
||||||||
| 20 | Binding and Uptake of Ligands by Scavenger Receptors | 42 | 0.415 | |||||
|
||||||||
| 21 | Transcriptional regulation of pluripotent stem cells | 24 | 0.415 | |||||
|
||||||||
| 22 | Photodynamic therapy-induced NF-kB survival signaling | 48 | 0.415 | |||||
|
||||||||
| 23 | Circadian Clock | 85 | 0.415 | |||||
|
||||||||
| 24 | Clear cell renal cell carcinoma pathways | 85 | 0.415 | |||||
|
||||||||
| 25 | Signaling by Receptor Tyrosine Kinases | 524 | 0.415 | |||||
|
||||||||
| 26 | Mitochondrial complex IV assembly | 31 | 0.415 | |||||
|
||||||||
| 27 | Transcription Ligand-dependent activation of the ESR1/SP pathway | 51 | 0.415 | |||||
|
||||||||
| 28 | 3q29 copy number variation syndrome | 62 | 0.415 | |||||
|
||||||||
| 29 | Angiogenesis (WikiPathways) | 19 | 0.415 | |||||
|
||||||||
| 30 | Network map of SARS-CoV-2 signaling pathway | 48 | 0.415 | |||||
|
||||||||
| 31 | ERK Signaling | 1185 | 0.415 | |||||
|
||||||||
| 32 | Deubiquitination | 298 | 0.415 | |||||
|
||||||||
| 33 | AP-1 transcription factor network | 69 | 0.415 | |||||
|
||||||||
| 34 | NAD metabolism, sirtuins and aging | 11 | 0.415 | |||||
|
||||||||
| 35 | Notch Signaling Pathways | 100 | 0.415 | |||||
|
||||||||
| 36 | Vesicle-mediated transport | 673 | 0.415 | |||||
|
||||||||
| 37 | 11p11.2 copy number variation syndrome | 144 | 0.415 | |||||
|
||||||||
| 38 | Lipid metabolism pathway | 17 | 0.415 | |||||
|
||||||||
| 39 | Adipogenesis | 131 | 0.415 | |||||
|
||||||||
| 40 | p70S6K Signaling | 392 | 0.415 | |||||
|
||||||||
| 41 | Neovascularisation processes | 34 | 0.415 | |||||
|
||||||||
| 42 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 74 | 0.415 | |||||
|
||||||||
| 43 | p53 Signaling | 117 | 0.415 | |||||
|
||||||||
| 44 | Epithelial to mesenchymal transition in colorectal cancer | 161 | 0.415 | |||||
|
||||||||
| 45 | Angiotensin II receptor type 1 pathway | 28 | 0.415 | |||||
|
||||||||
| 46 | Cytokine Signaling in Immune system | 732 | 0.415 | |||||
|
||||||||
| 47 | Pre-NOTCH Expression and Processing | 235 | 0.415 | |||||
|
||||||||
| 48 | Unfolded Protein Response (UPR) | 94 | 0.415 | |||||
|
||||||||
| 49 | Interleukin-4 and Interleukin-13 signaling | 108 | 0.415 | |||||
|
||||||||
| 50 | VEGFA-VEGFR2 signaling | 154 | 0.415 | |||||
|
||||||||
| 51 | Nervous system development | 1168 | 0.415 | |||||
|
||||||||
| 52 | Metabolism | 2121 | 0.415 | |||||
|
||||||||
| 53 | Congenital generalized lipodystrophy | 17 | 0.415 | |||||
|
||||||||
| 54 | lncRNA-mediated mechanisms of therapeutic resistance | 6 | 0.415 | |||||
|
||||||||
| 55 | Th17 cell differentiation pathway | 69 | 0.415 | |||||
|
||||||||
| 56 | Sudden infant death syndrome (SIDS) susceptibility pathways | 159 | 0.415 | |||||
|
||||||||
| 57 | Lipid particle organization | 6 | 0.415 | |||||
|
||||||||
| 58 | Signal Transduction | 2590 | 0.415 | |||||
|
||||||||
| 59 | Orexin receptor pathway | 24 | 0.415 | |||||
|
||||||||
| 60 | Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids | 7 | 0.415 | |||||
|
||||||||
| 61 | HIF1A and PPARG regulation of glycolysis | 8 | 0.415 | |||||
|
||||||||
| 62 | Malignant pleural mesothelioma | 409 | 0.415 | |||||
|
||||||||
| 63 | Signaling by PTK6 | 54 | 0.415 | |||||
|
||||||||
| 64 | Development_Leptin signaling via JAK/STAT and MAPK cascades | 28 | 0.415 | |||||
|
||||||||
| 65 | VEGFR1 specific signals | 25 | 0.415 | |||||
|
||||||||
| 66 | Translation Insulin regulation of translation | 183 | 0.415 | |||||
|
||||||||
| 67 | Notch-mediated HES/HEY network | 45 | 0.415 | |||||
|
||||||||
| 68 | Innate Immune System | 2025 | 0.415 | |||||
|
||||||||
| 69 | Hepatitis C and hepatocellular carcinoma | 55 | 0.415 | |||||
|
||||||||
| 70 | Signaling by ALK | 27 | 0.415 | |||||
|
||||||||